跳到正文
原文
Endpoints News 生物医药· Max Gelman·· 2 天前AI 评分48

FDA就ivonescimab拒信提示VEGF相关安全性担忧并称获益较有限

FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk

AI 导读

FDA在向Summit Therapeutics和Akeso发出的拒信中,对癌症药物ivonescimab的安全性表示关注,并指出其临床获益相比毒性风险为

正文

The FDA sig­naled new in­ter­est in the safe­ty of Sum­mit Ther­a­peu­tics and Ake­so’s can­cer drug ivonescimab, say­ing that it turned down the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news